Skip to Content
Merck
CN

R-015

Supelco

Rufinamide solution

500 μg/mL in methanol, ampule of 1 mL, certified reference material

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C10H8F2N4O
CAS Number:
Molecular Weight:
238.19
EC Number:
UNSPSC Code:
41116107
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

concentration

500 μg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChI key

POGQSBRIGCQNEG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

An antiepileptic drug and anticonvulsant, Rufinamide is approved for the treatment of partial seizures associated with Lennox-Gastaut syndrome in adults and children 4 years and older.

Legal Information

Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Trevor Resnick et al.
Epileptic disorders : international epilepsy journal with videotape, 13 Suppl 1, S27-S43 (2011-06-18)
Rufinamide is a triazole derivative structurally unrelated to other antiepileptic drugs that is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. Originally granted orphan drug status, marketing authorisation was obtained on
Iolanda Mazzucchelli et al.
Analytical and bioanalytical chemistry, 401(3), 1013-1021 (2011-06-07)
The development of a simple and rapid high-performance liquid chromatography (HPLC) method for the determination of the new antiepileptic drug rufinamide (RFN) in human plasma and saliva is reported. Samples (250 μl) are alkalinized with ammonium hydroxide (pH 9.25) and
Shin Hye Kim et al.
Seizure, 21(4), 288-291 (2012-03-17)
To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included
Romina Moavero et al.
Epilepsy research, 102(1-2), 94-99 (2012-06-09)
Rufinamide is a new antiepileptic drug approved as add-on treatment in Lennox-Gastaut syndrome from the age of 4 years, and for the treatment of focal seizures in adults and adolescents. The aim of this prospective study was to evaluate the
Se Hee Kim et al.
Epileptic disorders : international epilepsy journal with videotape, 15(1), 49-54 (2013-03-28)
We evaluated the efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy. The study cohort consisted of 20 patients with Lennox-Gastaut syndrome, 5 with Dravet syndrome, and 28 with unclassified refractory generalised epilepsy. Patients with more

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service